Delayed protection against ventricular arrhythmias by monophosphoryl lipid-A in a canine model of ischaemia and reperfusion

European Journal of Pharmacology

Volumn 382, Issue 2, 1999, Pages 81-90

  Végh, Ágnes ^a   György, Katalin ^a   Rastegar, Mohamed Ali ^a   Papp, Julius Gy ^a   Parratt, James R ^b  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Aminoguanidine; Bacterial endotoxin; Ischaemia; Meclofenamate; Monophosphoryl lipid A; Nitric oxide (NO); Reperfusion; Ventricular arrhythmias

Indexed keywords

AMINOGUANIDINE; MECLOFENAMIC ACID; NITRIC OXIDE SYNTHASE; PHOSPHORYL LIPID A; PROSTAGLANDIN SYNTHASE; PROSTANOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORONARY HEMODYNAMICS; DISEASE SEVERITY; DOG; DRUG EFFECT; DRUG MECHANISM; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; ARTERIAL OCCLUSIVE DISEASES; CORONARY VESSELS; DISEASE MODELS, ANIMAL; DOGS; ENZYME INHIBITORS; FEMALE; GUANIDINES; HEART VENTRICLES; HEMODYNAMIC PROCESSES; LIPID A; MALE; MECLOFENAMIC ACID; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SEVERITY OF ILLNESS INDEX; TACHYCARDIA, VENTRICULAR; TIME FACTORS; VENTRICULAR FIBRILLATION;

EID: 17744404762     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00557-9     Document Type: Article

References (47)

1. Astiz M.E., Rackow E.C., Still G.J., Howell S.T., Cato A., Von Eschen K.B., Ulrich J.T., Rudbach J.A., McMahon G., Vargas R., Stern W. Pretreatment of normal humans with monophosphoryl lipid-A induces tolerance to endotoxin: a prospective, double blind, randomized, controlled trial. Crit. Care Med. 23:1995;9-17.
2. Baxter G.F., Goodwin R.W., Wright M.J., Kerac M., Heads R.J., Yellon D.M. Myocardial protection after monophosphoryl lipid-A: studies of delayed anti-ischaemic properties in rabbit heart. Br. J. Pharmacol. 117:1996;1685-1692.
3. Bolli R., Bhatti Z.A., Tang X.-L., Zhang Q., Guo Y., Jadoon A.K. Evidence that the late preconditioning against myocardial stunning in conscious rabbits is triggered by the generation of nitric oxide. Circ. Res. 81:1997;42-52.
4. Bolli R., Dawn B., Tang X.-L., Qiu Y., Ping P., Zhang J., Takano H. Delayed preconditioning against myocardial stunning. Baxter G.F., Yellon D.M. Delayed Preconditioning and Adaptive Cardioprotection. 1998;29-47 Kluwer Academic Publishers.
5. Brown J.M., Grosso M.A., Terada L.S., Whitman G.J.R., Banerjee A., White C.W., Harken A.H., Pepine J.E. Endotoxin pretreatment increases endogenous myocardial catalase activity and decreases ischaemia-reperfusion injury of isolated rat heart. Proc. Natl. Acad. Sci. U.S.A. 86:1989;2526-2530.
6. Depre C., Hue L. Cyclic GMP in the perfused rat heart: effect of ischemia, anoxia and nitric oxide synthase inhibitor. FEBS Lett. 345:1994;241-245.
7. Elliott G.T., Comerford M.L., Smith J.R., Zhao L. Myocardial ischaemia/reperfusion protection using monophosphoryl lipid-A is abrogated by the ATP-sensitive potassium channel blocker, glibenclamide. Cardiovasc. Res. 32:1996;1071-1080.
8. Gross G.J. Endotoxin, monophosphoryl lipid-A and delayed cardioprotection. Baxter G.F., Yellon D.M. Delayed Preconditioning and Adaptive Cardioprotection. 1998;171-189 Kluwer Academic Publishers.
9. Grover G.J. Role of ATP-sensitive potassium channels in myocardial preconditioning. Wainwright C.L., Parratt J.R. Myocardial Preconditioning. 1996;129-146 Springer, Berlin.
10. Julou-Schaeffer G., Gray G.A., Fleming I., Schott C., Parratt J.R., Stoclet J.-C. Loss of vascular responsiveness induced by endotoxin involves the L-arginine pathway. Am. J. Physiol. 259:1990;H1038-H1043.
11. Kaszala K., Végh Á., Papp J.Gy., Parratt J.R. Time-course of the protection against ischaemia and reperfusion-induced ventricular arrhythmias resulting from brief periods of cardiac pacing. J. Mol. Cell. Cardiol. 28:1996;2085-2095.
12. Kis A., Végh Á., Papp J.Gy., Parratt J.R. Repeated pacing extends the time during which canine hearts are protected against ischaemia-induced arrhythmias: role of nitric oxide. J. Mol. Cell. Cardiol. 31:1999;1229-1243.
13. Kis A., Végh Á., Papp J.Gy., Parratt J.R. Pacing-induced delayed protection against arrhythmias is attenuated by aminoguanidine, an inhibitor of nitric oxide synthase. Br. J. Pharmacol. 127:1999;1545-1550.
14. Madonna G.S., Peterson J.E., Ribi E.E., Vogel S.N. Early phase endotoxin tolerance induction by a detoxified lipid-A derivative, monophosphoryl lipid-A. Infect. Immun. 52:1986;6-11.
15. Maulik N., Tosaki Á., Elliott G.T., Maulik G., Das D.K. Induction of iNOS gene expression by monophosphoryl lipid-A: a pharmacological approach for myocardial adaptation to ischemia. Drugs Exp. Clin. Res. 24:1998;117-124.
16. McDonough K.H., Causey K.M. Effects of sepsis on recovery of the heart from 50 min ischaemia. Shock. 1:1994;432-437.
17. ATP channels mediate late preconditioning against infarction produced by monophosphoryl lipid-A. Am. J. Physiol. 271:1996;H2723-H2729.
18. Node K., Kitakaze M., Kosaka H., Komamura K., Minamino T., Tada M., Inoue M., Hori M., Kamada T. Plasma nitric oxide end products are increased in the ischemic canine heart. Biochem. Biophys. Res. Commun. 211:1995;370-374.
19. ATP channels in ischaemic preconditioning. Cardiovasc. Res. 28:1994;783-787.
20. Parratt J.R., Szekeres L. Delayed protection of the heart against ischaemia. Trends Pharmacol. Sci. 16:1995;352-355.
21. Parratt J.R., Végh Á. Endothelial cells, nitric oxide and ischaemic preconditioning. Basic Res. Cardiol. 91:1996;27-30.
22. Parratt J.R., Végh Á. Delayed protection against ventricular arrhythmias by cardiac pacing. Heart. 78:1997;423-425.
23. Przyklenk K., Zhao L., Kloner R.A., Elliott G.T. Cardioprotection with ischaemic preconditioning and MLA: role of adenosine-regulating enzymes? Am. J. Physiol. 271:1996;H1004-H1014.
24. Qureshi N., Takayama K., Ribi E.E. Purification and structural determination of nontoxic lipid-A obtained from lipopolysaccharide of Salmonella typhimurium. J. Biol. Chem. 257:1982;11808-11815.
25. Radomski M.W., Palmer R.M.J., Moncada S. Glucocorticoids inhibit the expression of an inducible, but not the constitutive nitric oxide synthase in vascular endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 87:1990;10043-10047.
26. Rowland R.T., Cleveland J.C., Meng C., Ao L., Harken A.H., Brown J.M. A single endotoxin challenge induces delayed myocardial protection against infarction. J. Surg. Res. 63:1996;193-198.
27. 2+-independent nitric oxide synthase in the myocardium. Br. J. Pharmacol. 105:1992;575-580.
28. Schulz R., Panas D.L., Catena R., Moncada S., Olley P.M., Lopaschuk G.D. The role of nitric oxide in cardiac depression induced by interleukin-1β and tumor necrosis factor-α Br. J. Pharmacol. 114:1995;27-34.
29. Stoclet J.-C., Fleming I., Gray G.A., Julou-Schaeffer G., Schneider F., Schott C., Parratt J.R. Nitric oxide and endotoxaemia. Circulation. 87:1993;V77-V80. (suppl. V).
30. Takayama K., Ribi E.E., Cantrell J.L. Isolation of a nontoxic lipid-A fraction containing tumour regression activity. Cancer Res. 41:1981;2654-2657.
31. Takayama K., Qureshi N., Ribi E.E., Cantrell J.L. Separation and characterization of toxin and nontoxic forms of lipid-A. Rev. Infect. Dis. 6:1984;439-443.
32. Végh Á., Parratt J.R. Delayed preconditioning against ventricular arrhythmias. Baxter G.F., Yellon D.M. Delayed Preconditioning and Adaptive Cardioprotection. 1998;63-91 Kluwer Academic Publishers.
33. Végh Á., Szekeres L., Parratt J.R. Protective effects of preconditioning of the ischaemic myocardium involve cyclo-oxygenase products. Cardiovasc. Res. 24:1990;1020-1023.
34. Végh Á., Komori S., Szekeres L., Parratt J.R. Antiarrhythmic effects of preconditioning in anaesthetised dogs and rats. Cardiovasc. Res. 26:1992;487-495.
35. Végh Á., Papp J.Gy., Szekeres L., Parratt J.R. Are ATP sensitive potassium channels involved in the pronounced antiarrhythmic effects of preconditioning? Cardiovasc. Res. 27:1993;638-643.
36. Végh Á., Papp J.Gy., Parratt J.R. Prevention by dexamethasone of the marked antiarrhythmic effects of preconditioning induced 20 h after rapid cardiac pacing. Br. J. Pharmacol. 113:1994;1081-1082.
37. Végh Á., Papp J.Gy., Elliott G.T., Parratt J.R. Pretreatment with monophosphoryl lipid-A (MPL-C) reduces ischaemia reperfusion-induced arrhythmias in dogs. J. Mol. Cell. Cardiol. 28:1996;A56.
38. Wainwright C.L., Parratt J.R. Failure of cyclo-oxygenase inhibition to protect against arrhythmias induced by ischaemia and reperfusion: implications for the role of prostaglandins as endogenous myocardial protective substances. Cardiovasc. Res. 25:1991;93-100.
39. Walker M.J.A., Curtis M.J., Hearse D.J., Campbell R.W.F., Janse M.J., Yellon D.M., Cobbe S.M., Coker S.J., Harness J.B., Harron D.W.G., Higgins A.J., Julian D.G., Lab M.J., Manning A.S., Northover B.J., Parratt J.R., Riemersma R.A., Riva E., Russel D.C., Sheridan D.J., Winslow E., Woodward B. The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia, infarction, and reperfusion. Cardiovasc. Res. 22:1988;447-455.
40. Wu S., Furman B.L., Parratt J.R. Attenuation by dexamethasone of endotoxin protection against ischaemia-induced ventricular arrhythmias. Br. J. Pharmacol. 113:1994;1083-1084.
41. Wu S., Furman B.L., Parratt J.R. Delayed protection against ischaemia-induced ventricular arrhythmias and infarct size limitation by the prior administration of Escherichia coli endotoxin. Br. J. Pharmacol. 118:1996;2157-2163.
42. Wu S., Furman B.L., Parratt J.R. Monophosphoryl lipid-A reduces both arrhythmia severity and infarct size in a rat model of ischaemia. Eur. J. Pharmacol. 345:1998;285-287.
43. Yao Z., Auchampach J.A., Pieper G.M., Gross G. Cardioprotective effects of monophosphoryl lipid-A, a novel endotoxin analogue, in the dog. Cardiovasc. Res. 27:1993;832-838.
44. Yao Z., Rasmussen J.L., Hirt J.L., Mei D.A., Pieper G.M., Gross G.J. Effects of monophosphoryl lipid-A on myocardial ischaemia/reperfusion injury in dogs. J. Cardiovasc. Pharmacol. 22:1993;653-663.
45. Zhao L., Kirsch C.C., Hagen S.R., Elliott G.T. Preservation of global cardiac function in the rabbit following protracted ischaemia/reperfusion using monophosphoryl lipid-A (MLA). J. Mol. Cell. Cardiol. 28:1996;197-208.
46. Zhao L., Weber P.A., Smith J.R., Comerford M.L., Elliott G.T. Role of inducible nitric oxide synthase in pharmacological "preconditioning" with monophosphoryl lipid-A. J. Mol. Cell. Cardiol. 29:1997;1567-1576.
47. Zweier J.L., Wang P., Kuppusamy P. Direct measurement of nitric oxide generation in the ischemic heart using electron paramagnetic resonance spectroscopy. J. Biol. Chem. 270:1995;304-307.